ALERT: This system is being upgraded on Tuesday December 12. It will not be available
for use for several hours that day while the upgrade is in progress. Deposits to DukeSpace
will be disabled on Monday December 11, so no new items are to be added to the repository
while the upgrade is in progress. Everything should be back to normal by the end of
day, December 12.
Browsing by Subject "Double-Blind Method"
Now showing items 1-20 of 48
-
A Phase II Randomized Clinical Trial of the Safety and Efficacy of Intravenous Umbilical Cord Blood Infusion for Treatment of Children with Autism Spectrum Disorder.
(The Journal of pediatrics, 2020-07)<h4>Objective</h4>To evaluate whether umbilical cord blood (CB) infusion is safe and associated with improved social and communication abilities in children with autism spectrum disorder (ASD).<h4>Study design</h4>This ... -
A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.
(BMC Infect Dis, 2014-05-23)BACKGROUND: Staphylococcus aureus bacteremia is a common infection associated with significant morbidity and mortality. Telavancin is a bactericidal lipoglycopeptide active against Gram-positive pathogens, including ... -
A randomized, double-blind, placebo-controlled trial of pramipexole augmentation in treatment-resistant major depressive disorder.
(The Journal of clinical psychiatry, 2013-07)<h4>Background</h4>Multiple treatments for patients with major depressive disorder (MDD) have demonstrated efficacy, but up to one-third of individuals with MDD do not achieve symptomatic remission despite various interventions. ... -
A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation.
(Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019-01)<h4>Background</h4>Clostridium difficile-associated diarrhea (CDAD) is common during hematopoietic stem-cell transplantation (HSCT) and is associated with increased morbidity and mortality. We evaluated fidaxomicin for prevention ... -
Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine.
(Drug Des Devel Ther, 2013)OBJECTIVE: MAP0004 is an investigational product which delivers dihydroergotamine (DHE) through the lung via a breath-synchronized metered dose inhaler. The objective of this study was to compare the acute effects of orally ... -
Bupropion and Naltrexone in Methamphetamine Use Disorder.
(The New England journal of medicine, 2021-01)<h4>Background</h4>The use of naltrexone plus bupropion to treat methamphetamine use disorder has not been well studied.<h4>Methods</h4>We conducted this multisite, double-blind, two-stage, placebo-controlled trial with ... -
Changes in serum and synovial fluid biomarkers after acute injury (NCT00332254).
(Arthritis Res Ther, 2010)INTRODUCTION: Acute trauma involving the anterior cruciate ligament is believed to be a major risk factor for the development of post-traumatic osteoarthritis 10 to 20 years post-injury. In this study, to better understand ... -
Colchicine effectiveness in symptom and inflammation modification in knee osteoarthritis (COLKOA): study protocol for a randomized controlled trial.
(Trials, 2015-04-30)BACKGROUND: Despite the high prevalence and global impact of knee osteoarthritis (KOA), current treatments are palliative. No disease modifying anti-osteoarthritic drug (DMOAD) has been approved. We recently demonstrated ... -
Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants.
(American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2013-09)<h4>Purpose</h4>The cost-effectiveness of voriconazole versus fluconazole prophylaxis against fungal infections in hematopoietic cell transplant (HCT) recipients is investigated.<h4>Methods</h4>A decision-analytic model ... -
Consistent improvement with eculizumab across muscle groups in myasthenia gravis.
(Annals of clinical and translational neurology, 2020-08)<h4>Objective</h4>To assess whether eculizumab, a terminal complement inhibitor, improves patient- and physician-reported outcomes (evaluated using the myasthenia gravis activities of daily living profile and the quantitative ... -
Continuous intravenous cimetidine decreases stress-related upper gastrointestinal hemorrhage without promoting pneumonia.
(Crit Care Med, 1993-01)OBJECTIVES: To determine whether a continuous i.v. infusion of cimetidine, a histamine-2 (H2) receptor antagonist, is needed to prevent upper gastrointestinal (GI) hemorrhage when compared with placebo and if that usage ... -
Early outcomes following low dose naltrexone enhancement of opioid detoxification.
(The American journal on addictions, 2009-03)Although withdrawal severity and treatment completion are the initial focus of opioid detoxification, post-detoxification outcome better defines effective interventions. Very low dose naltrexone (VLNTX) in addition to methadone ... -
Effect of the S-nitrosoglutathione reductase inhibitor N6022 on bronchial hyperreactivity in asthma.
(Immunity, inflammation and disease, 2018-06)<h4>Rationale</h4>Patients with asthma demonstrate depletion of the endogenous bronchodilator GSNO and upregulation of GSNOR.<h4>Objectives</h4>An exploratory proof of concept clinical study of N6022 in mild asthma to determine ... -
Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial.
(The Lancet. Infectious diseases, 2023-04)<h4>Background</h4>Lower respiratory tract infections are frequently treated with antibiotics, despite a viral cause in many cases. It remains unknown whether low procalcitonin concentrations can identify patients with lower ... -
Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.
(The Lancet. Respiratory medicine, 2021-12)<h4>Background</h4>Functional impairment of interferon, a natural antiviral component of the immune system, is associated with the pathogenesis and severity of COVID-19. We aimed to compare the efficacy of interferon beta-1a ... -
High dosage folic acid supplementation, oral cleft recurrence and fetal growth.
(International journal of environmental research and public health, 2013-02-04)<h4>Objectives</h4>To evaluate the effects of folic acid supplementation on isolated oral cleft recurrence and fetal growth.<h4>Patients and methods</h4>The study included 2,508 women who were at-risk for oral cleft recurrence ... -
Impact of fibrinogen levels on angiographic progression and 12-year survival in the armed forces regression study.
(Angiology, 2010-05)We assessed the role of fibrinogen levels on angiographic progression and long-term survival among 111 patients with coronary disease enrolled in the Armed Forces Regression Study (AFREGS). Baseline fibrinogen levels and ... -
Impact of increases in high-density lipoprotein cholesterol on cardiovascular outcomes during the armed forces regression study.
(J Cardiovasc Pharmacol Ther, 2010-12)INTRODUCTION: high-density lipoprotein (HDL) cholesterol is a well-established inverse risk factor for cardiovascular disease. The extent to which cardiovascular risk can be modified through changes in HDL, however, is less ... -
Improved muscle function in a phase I/II clinical trial of albuterol in Pompe disease.
(Molecular genetics and metabolism, 2020-02)This 24-week, Phase I/II, double-blind, randomized, placebo-controlled study investigated the safety and efficacy of extended-release albuterol in late-onset Pompe disease stably treated with enzyme replacement therapy at ... -
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.
(Journal of the American Heart Association, 2015-08-25)<h4>Background</h4>CSL112 is a new formulation of human apolipoprotein A-I (apoA-I) being developed to reduce cardiovascular events following acute coronary syndrome. This phase 2a, randomized, double-blind, multicenter, ...
